

REMARKS

Claims 1-68 are currently pending in the application. Claims 28-66 are withdrawn. Claims 23, and 26 are cancelled. No new matter is added.

Rejection of Claims 23 and 26 Under 35 U.S.C. §112, First Paragraph

The Office Action states that claims 23 and 26 are rejected under 35 U.S.C. §112, first paragraph on the grounds that they allegedly fail to comply with the written description requirement. The Office Action states that the limitation that the second amino acid sequence comprise at least five contiguous amino acids of a naturally occurring GM-CSF is directed at a genus, and further states that Applicants fail to provide adequate written description of the genus by providing sufficient description of a representative number of species. Applicants traverse the rejection.

Without acquiescing to the rejection, or surrendering its rights to pursue the subject matter of claims 23 and 26 in a continuing application, Applicant has cancelled claims 23 and 26, thus rendering the instant rejection moot. Applicant requests reconsideration and withdrawal of the rejection.


Double Patenting

The Office Action states that the instant claims are rejected under the judicially created doctrine of obviousness type double patenting in view of several co-pending applications. Applicant is filing a terminal disclaimer herewith to obviate the double patenting rejection.

Applicants submit that all claims are allowable as written and respectfully request early favorable action by the Examiner. If the Examiner believes that a telephone conversation with Applicant's attorney/agent would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned attorney/agent of record.

Date: December 27, 2006

Respectfully submitted,



Name: Matthew Beaudet

Registration No.: 50,649

Customer No.: 21874

Edwards Angell Palmer & Dodge LLP

P.O. Box 55874

Boston, MA 02205

Tel. (617) 239-0100